Programme Outline and Topics

Topics include:

  • Endocrinology of cardiovascular disease
  • Targeting the ACE2/Ang 1-7 axis of the RAAS
  • AT2 Receptors
  • Metabolic aspects of cardiovascular disease
  • Molecular mechanisms of hypertension
  • Therapeutic interventions targeting the RAAS (ARNI/Angiotensinogen siRNA)
  • Cardioprotection and interventions for heart failure
Provisional Programme
Wednesday, 28 November
16:00-16:40 Welcome
16:00-16:40 Genetics of primary aldosteronism and the new physiology of aldosterone production Maria Christina Zennaro (INSERM)
16:40-17:20 Endocrine Hypertension: Facts and Fictions Gian Paolo Rossi (University of Padova)
17:20-18:00 Development of an inducible and reversible mouse model of aldosterone excess Matthew Taylor (University of Michigan)
18:15 Welcome Cocktail
Thursday, 29 November
Cardioprotection and Interventions for Heart Failure
08:30-09:10 Bromocriptine in Peripartum Cardiomyopathy presenting in acute heart failure Karen Sliwa-Hahnle (University of Cape Town)
09:10-09:50 Aortic reflected waves in risk determination Gavin Norton (University of Witwatersrand)
09:50-10:30 Aortic stiffness as a determinant of cardiovascular events beyond brachial and aortic blood pressure Angela Woodiwis (University of Witwatersrand)
10:30-11:00 Selected talks from abstracts
11:00-11:30 TEA
11h30-12h10 AT2-receptor agonists: The long way from identifying a new pharmacological target to first clinical studies in humans Muscha Steckelings  (University of Southern Denmark)
12:10-12h50 Protective Effects of the Renin-Angiotensin System in the Brain: Stroke and Hypertension Colin Sumners (University of Florida)
12:50-13:05 Selected talk from abstracts
13:05-14:00 LUNCH
Profiling of the RAAS
14:00-14:40 A detailed profile of the RAAS Fingerprint in young healthy black and white adults: The African-PREDICT study Alta Schutte (Northwest University)
14:40-15:20 RAAS-Triple A testing: Angiotensin based biomarkers in the personalized treatment of hypertension Marko Poglitsch (AttoquantDiagnostics)
15:20-16:00 Physiological treatment of resistant hypertension: importance of renin and aldosterone profile Brian Rayner (University of Cape Town)
16:00-16:20 TEA
From Alatensins to Ang 1-9
16:20-17:00 Going beyond the classic paradigm:alatensins Robson Santos (Federal University of Minas Gerais)


Ang-(1-7)/Mas and ET-1/ETBR- a new partnership


Rhian Touyz (University of Glasgow)
17:40-18:20 Assessing angiotensin-(1-9) function in acute vascular injury and neointima formation Stuart Nicklin (University of Glasgow)
19:00 Conference dinner
Friday, 30 November
Therapeutic interventions targeting the RAAS
08:30-09:10 Renin-angiotensin-aldosterone system inhibition: can we do better? Focus on ARNI and angiotensinogen suppression. Jan Danser (Erasmus MC)
09:10-09:50 Central-acting aminopeptidase A inhibitors for new treatment of hypertension and heart failure: from discovery to clinical trial Catherine Llorens-Cortes (INSERM)
09:50-10:30 Inhibition of ACE C-domain and neprilysin in a chronic  angiotesnin II-dependent mouse model of hypertension Ed Sturrock (University of Cape Town)
10:30-11:00 TEA
Endocrinology and Immunology of the RAAS
11:00-11:40 Exploring links between perturbed immunometabolic pathways and risk for CVD onset in HIV-positive individuals FaadielEssop (University of Stellenbosch)

The novel nonapeptideacein targets

angiotensin converting enzyme in the brain

and induces dopamine release

Jean Martinez (University of Montpellier) – TBC
12:15-12:30 Selected talk from abstracts
12:30 Closing remarks Rhian Touyz and Ed Sturrock